Summary
Changes in urine cytology and bladder mucosal architecture were observed during and following BCG treatment. Urine cytology changed from neoplastic to a normal pattern on the third, fourth and fifth treatments. In the first few hours after BCG treatment there was an increase in mononuclear cells in the urine. This increased with every treatment. A few days after treatment most of the white blood cells in the urine were polymorphonuclear.
The mucosa was not shed during the treatment, but later it was much thinner than an untreated mucosa. During and right after BCG treatment there were inflammatory changes in the submucosa which subsided after 6 months.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Bloomberg SD, Brosman SA, Hausman MS, Cohen A, Battenberg JD (1975) The effect of BCG on the dog bladder. Invest Urol 12:423–427
Brosman SA (1982) Experience with bacillus-Calmette-Guerin in patients with superficial bladder cancer. J Urol 128:27–30
Guinan P, Shaw M, Ray V (1986) Histopathology of BCG and thiotepa treated bladder. Urol Res 14:211–215
Haaff EO, Ratliff TL (1986) Detection of Interleukin 2 in the urine of patients with superficial bladder tumors after treatment with intravesical BCG. 81st AUA meeting. Abstract 567
Herr HW, Pinsky CM, Whitmore WF Jr., Oettgea HF, Melamed MR (1983) Effect of intravesical bacillus Calmette-Guerin (BCG) on carcinoma in situ of the bladder. Cancer 51:1323–1326
Kelley DR, Ratliff TL, Catalona WJ, Shapiro A, Lage JM, Bauer WC, Haaff EO, Dresner SM (1985) Intravesical bacillus Calmette-Guerin therapy for superificial bladder cancer: Effect of bacillus Calmette-Guerin viability on treatment results. J Urol 134:48–53
Lamm DL, Thor DE, Stogdill VD, Radwin HM (1982) Bladder cancer immunotherapy. J Urol 128:931–935
Martinez-Piniero JA, Muntanole P (1977) Nonspecific immunotherapy with BCG vaccine in bladder tumors. Eur Urol 3:11–12
Meijden APM, Steerenberg PA, de Jong WH, Bogman MJJT, Feitz WFJ, Hendriks BT, Debruyne FMJ, Ruitenberg EJ (1986) The effects of intravesical and intradermal application of a new BCG on the dog bladder. Urol Res 14:207–210
Morales A, Eidinger D, Bruce AW (1976) Intracavitary bacillus Calmette-Guerin in the treatment of superficial bladder tumors. J Urol 116:180–183
Morales A (1984) Long-term results and complications of intracavitary bacillus Calmette-Guerin therapy for bladder cancer. J Urol 132:457–459
Ratliff TL, Shapiro A, Kelley DR, Catalona WJ (1984) Effects of intravesical BCG on immune parameters. 79th AUA meeting. Abstract 783
Shapiro A, Ratliff TL, Oakley DM, Catalona WJ (1983) Reduction of bladder tumor growth in mice treated with intravesical bacillus Calmette-Guerin and its correlation with bacillus Calmette-Guerin viability and natural killer cell activity. Cancer Res 43:1611–1615
Shapiro A, Ratliff TL, Oakley DM, Catalona WJ (1983) Comparison of the anti-tumor activity of BCG and chemotherapeutic agents against a mouse bladder tumor. 78th AUA meeting. Abstract 68
Zbar B, Rapp HJ (1974) Immunotherapy of guinea pig cancer with BCG. Cancer 34:1532–1540
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Shapiro, A., Lijovetzky, G. & Pode, D. Changes of the mucosal architecture and of urine cytology during BCG treatment. World J Urol 6, 61–64 (1988). https://doi.org/10.1007/BF00326845
Issue Date:
DOI: https://doi.org/10.1007/BF00326845